RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 13 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 13

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  3. Study siteCancer Hospital, Shandong First Medical University山东省肿瘤医院JinanHospital page
  4. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  5. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  6. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  7. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  8. Study siteJiangsu Provincial People's Hospital江苏省人民医院(南京医科大学第一附属医院)NanjingHospital page
  9. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  10. Study siteShantou Central Hospital汕头市中心医院ShantouHospital page
  11. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  12. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  13. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07003074, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology

    Inclusion criterion 3

  3. Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment

    Exclusion criterion 5

    Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment

    Exclusion criterion 28

  4. Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1

    Inclusion criterion 2

  5. Have at least one measurable lesion according to RECIST 1.1 criteria;

    Inclusion criterion 7

  6. Have had or currently have other malignant tumors within the past 5 years of randomization

    Exclusion criterion 4

    History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07003074, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects voluntarily enrolled in this study with good compliance
  • Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1
  • HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology
  • Defined hormone receptor (HR) status
  • Has not received systemic anti-tumor therapy during the recurrence/metastasis stage (acceptable ≤ first-line endocrine therapy)
  • If receiving (new) adjuvant therapy, it is required that the time interval between the end of systemic therapy (excluding endocrine therapy) and the discovery of recurrence/metastasis be greater than 12 months
  • Have at least one measurable lesion according to RECIST 1.1 criteria;
  • Good major organ function

Exclusion Criteria:

  • It is known that there is spinal cord compression or active central nervous system metastasis;
  • Subjects with only skin and/or brain lesions as target lesions
  • Combined diseases and medical history
  • Have had or currently have other malignant tumors within the past 5 years of randomization
  • Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment
  • Received major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to randomization
  • There are diseases that affect intravenous injection and venous blood collection
  • There are congenital bleeding and coagulation disorders present
  • An arterial/deep vein thrombosis event occurred within 6 months prior to the first administration
  • Poor blood pressure control
  • Suffering from significant cardiovascular disease
  • There is an uncontrolled infection of ≥ CTC AE grade 2 within 14 days before the start of treatment
  • History of interstitial lung disease/pneumonia (non infectious) requiring steroid medication intervention in the past
  • Individuals with moderate to severe pulmonary dysfunction/disease within 3 months prior to the first administration
  • Active viral hepatitis with poor control
  • Active syphilis infected individuals in need of treatment
  • Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation
  • Immunosuppressants or systemic or absorbable local hormone therapy are required to achieve immunosuppression
  • History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases
  • Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification>1.0 g
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis
  • Poor control of diabetes
  • Individuals with epilepsy who require treatment
  • Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders
  • Tumor related symptoms and treatment
  • There is a third interstitial fluid accumulation or cancerous lymphangitis that cannot be controlled by drainage or other methods
  • History of cumulative dose exposure to anthracyclines in the past
  • Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment
  • Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment
  • Research treatment related
  • Previously received antibody conjugate therapy consisting of topoisomerase I inhibitors,;
  • Allergic to any research drug or any ingredient or excipient in the drug;
  • Individuals who experience severe hypersensitivity reactions after using monoclonal antibodies;
  • Participated in other clinical trials of anti-tumor therapy within 4 weeks before the start of the research treatment.
  • According to the researcher's judgment, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study.

Quoted from ClinicalTrials.gov, NCT07003074, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07003074, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07003074